Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1309

Dupilumab

Home » Dupilumab

Background of Dupilumab

Dupilumab, marketed under the brand name Dupixent, is a monoclonal antibody that functions by blocking interleukin 4 and interleukin 13. It is indicated for the management of allergic conditions such as eczema (atopic dermatitis), asthma, and nasal polyps, which often lead to chronic sinusitis. Additionally, Dupilumab is utilized in the treatment of eosinophilic esophagitis and prurigo nodularis.

Specifications

Catalog Number:
KB-1309
Antibody Name:
Dupilumab
Isotype:
Human IgG4-S228P, kappa
FC Muations:
S228P/K447Del
Target:
IL4Ra
Species Reactivity:
Human
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
50 mM sodium citrate,150mM NaCl,pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
ELISA | FACS
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Buchheit KM, Sohail A, Hacker J, Maurer R, Gakpo D, Bensko JC, et al. (August 2022). "Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease". The Journal of Allergy and Clinical Immunology. 150 (2): 415–424.